Aplastic Anemia Pipeline Insight 2021: Emerging Drugs, Key
16 Jul 2021
Small molecular drugAntibodyVaccine
Los Angeles, USA, July 15, 2021 (GLOBE NEWSWIRE) -- Aplastic Anemia Pipeline Insight 2021: Emerging Drugs, Key Companies, Clinical Trials Updates
The rise in awareness of Aplastic Anemia has led to the increased Research & Development activities in the pharmaceutical sector and the development of pipeline products such as PF-06462700, REGN7257, Romiplostim, BL-8040, and others.
DelveInsight’s “Aplastic Anemia Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Aplastic Anemia pipeline landscapes. It comprises Aplastic Anemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Aplastic Anemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Aplastic Anemia pipeline products.
Some of the key takeaways from the Aplastic Anemia Pipeline Report
Get an overview of pipeline landscape @ Aplastic Anemia Clinical Trials Analysis
Aplastic Anemia is a rare, severe blood disorder due to failure of the bone marrow to produce blood cells. The disease can be moderate, painful, or very severe. Aplastic Anemia treatment is based on the severity. Treatment with immune system-suppressing therapy or a stem cell transplant is required for patients with severe Aplastic Anemia, whereas there is no standard of care for moderate Aplastic Anemia.
Aplastic Anemia Emerging Drugs
PF-06462700 is an immunosuppressant/immunosuppressive agent. PF-06462700 is being developed by Pfizer for Aplastic Anemia patients and is currently in the phase III stage of development.
Regeneron Pharmaceuticals is developing REGN7257 for Aplastic Anemia treatment. It is currently in phase I/II stage of development. LB-001 acts as a modulator of Interleukin 2 and immunomodular.
Romiplostim, a member of the thrombopoietin (TPO) mimetic class, is an Fc-peptide fusion protein (peptibody) that activates intracellular transcriptional pathways leading to increased platelet production via the TPO receptor. Romiplostim is currently being evaluated in Phase II/III clinical trials to treat patients with Aplastic Anemia.
BL-8040 (Motixafortide) targets CXCR4, a chemokine receptor and a well-validated therapeutic target that is over-expressed in many human cancers, including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis, therapeutic resistance, and CXCR4 overexpression correlated with poor prognosis. A Phase II clinical trial has been completed for BL-8040 for the treatment of Aplastic Anemia.
For further information, refer to the detailed report @ Aplastic Anemia Pipeline Therapeutics
Scope of Aplastic Anemia Pipeline Drug Insight
· Aplastic Anemia Therapies Late-stage (Phase III) · Aplastic Anemia Therapies Mid-stage (Phase II)· Aplastic Anemia Therapies Early-stage (Phase I) · Aplastic Anemia Pre-clinical stage and Discovery candidates · Discontinued and Inactive candidates
· Thrombopoietin receptor agonistsThrombopoietin receptor agonists· Anti-interleukin 2 receptor subunit gamma inhibitors· Cell replacements
· Vaccines· Monoclonal Antibody· Peptides· Polymer· Small molecule
· Infusion· Intradermal· Intramuscular· Intranasal· Oral· Parenteral· Subcutaneous· Topical
· Monotherapy· Combination· Mono/Combination
Key Questions regarding Current Aplastic Anemia Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Table of Contents
Get a customized pipeline report @ Aplastic Anemia Drugs Pipeline Report
Related Reports
DelveInsight's Aplastic Anemia - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Aplastic Anemia - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Aplastic Anemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Aplastic Anemia.
DelveInsight's Anemia In Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast - 2030 report proffers a detailed overview of the disease and understanding of historical and forecasted epidemiology.
DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
DelveInsight's Chemotherapy Induced Anemia - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
Browse Blog Posts
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.